Complimenting Traditional Research With Genomic Data in Urology

In a recent video interview with Applied Clinical Trials, Sujay Jadhav, CEO of Verana Health, discussed potential advancements the clinical research industry could see in 2025. Jadhav highlighted how unstructured data like physician notes and imaging data can be leveraged to improve disease identification and progression tracking. He also talked synthetic control arms and how they can replace expensive non-treatment arms, enhancing trial efficiency.

Jadhav: I think there's a number of areas and examples that we're seeing in our therapeutic areas that we focus on with real-world evidence. One is in the urology space around prostate cancer care and leveraging not just taking data that is available from EHR data, but also genomic data as well. Historically, when you look at prostate cancer, a lot of the reliance has been on traditional factors such as Gleason scores and PSA levels. Sometimes this results in overall under treatment of that particular disease, but I think complementing that with real-world data and genomic data, I think it can lead to better diagnosis of this and better understanding of the patient journey as well, and then allow you to tailor the treatment decisions and help improve recruitment with the overall clinical trial process. We’re seeing that actually play out quite a bit in the prostate cancer arena.